Skip to main content

Table 2 Changes of variables related with glucose metabolism after 12 weeks

From: Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity

  Baseline (mean±s.d.) 12 weeks (mean±s.d.) Mean changes from baseline (95% CI) Difference in mean change (95% CI)
HbA1c (%)     
Liraglutide added 8.79 ± 0.86 6.88 ± 0.64 -1.9 (-2.10, -1.72) ** -0.14 (-0.41, 0.13)
Insulin increaing 8.69 ± 0.91 6.93 ± 0.63 -1.77 (-2.00, -1.56) **  
PBG (mmol/L)     
Liraglutide added 8.36 ± 0.93 6.79 ± 0.48 -1.56 (-1.80, -1.33) ** 0.13 (0.15, -0.16)
Insulin increasing 8.41 ± 0.86 6.72 ± 0.46 -1.69 (-1.90, -1.48) **  
P2BG (mmol/L)     
Liraglutide added 13.76 ± 1.92 8.39 ± 1.17 -5.40 (-5.8, -4.92) ** -0.83 (-1.59, -0.07) #
Insulin increasing 13.80 ± 1.96 9.26 ± 1.19 -4.54 (-5.0, -4.0) **  
Body weight (kg)     
Liraglutide added 88.6 ± 11.8 82.9 ± 11.2 -5.62 (-6.51, -4.73) ** -7.6 (-8.67, -6. 57) ##
Insulin increasing 86.3 ± 10.3 88.3 ± 10.4 2.00 (1.52, 2.48) **  
BMI (kg/m2)     
Liraglutide added 30.4 ± 3.21 28.4 ± 3.04 -1.93 (-2.24, -1.63) ** -2.63 (-2.99, -2.67) ##
Insulin increasing 30.3 ± 2.98 31.00 ± 2.91 0.70 (0.53, 0.86) **  
Waist Circumference (cm)     
Liraglutide added 105.6 ± 12.6 99.9 ± 11.8 -5.70 (-6.5, -5.0) ** -7.5 (-8.4, -6.6) ##
Insulin increasing 104.6 ± 10.5 106.3 ± 10.4 1.76 (1.30, 2.23) **  
  1. Difference in mean change calculated as Liraglutide minus Insulin; CI, confidence interval; **p<0.01 for mean change from baseline in liraglutide and insulin; # p<0.05, ## p<0.01 for the between-treatment difference.